Industry Symposia

INDUSTRY SYMPOSIA PROGRAM (SATURDAY, APRIL 1, 2023)

Time	Session

13:00 14:00	Optimising COVID-19 Prevention for Nephrology Patients: Leaving No Patient Behind Organized by AstraZeneca Welcome and introduction Dr. Vuddhidej Ophascharoensuk (Chair) • COVID-19 situation update • Vaccination update Are vaccines the solution for everyone? Dr. Weerawat Manosuthi • The unmet need in high-risk groups despite vaccination • Monoclonal antibody therapy for prevention and treatment of COVID-19 Monoclonal antibody use: Clinical and Real-World data Dr. Behram Ali Khan • PROVENT/TACKLE overviews • Monoclonal antibody use in Singapore Q&A Moderated by Dr. Vuddhidej Ophascharoensuk (Chair) Ballroom 1	Non-steroidal MRAs: A new treatment pillar for chronic kidney disease in type 2 diabetes Organized by Bayer Welcome and introductions Masaomi Nangaku MRAs in 2023: still all the same? Angela Wang Slowing CKD progression and reducing CV events with Finerenone – From FIDELIO-DKD to FIDELITY Roberto Pecoits-Filho Close Masaomi Nangaku MR 109 ABFE	Atypical hemolytic uremic syndrome: closing the diagnosis-treatment gap Organized by Alexion AstraZeneca Rare Disease Chair’s welcome and introduction Prof. Shoichi Maruyama Pathophysiology of atypical hemolytic uremic syndrome Prof. Larry Greenbaum TMAs and aHUS: the importance of early diagnosis Prof. Paul Brinkkoetter Kidney transplant in patients with aHUS Prof. Julien Zuber Q & A session All speakers Closing remarks Prof. Shoichi Maruyama MR 109 CDHG	Understanding the role of complement in IgA nephropathy: Key to unlocking new treatment approaches Organized by Novartis Welcome and introduction Co-chairs: Jonathan Barratt The challenges with IgAN in clinical practice today Smeeta Sinha Complement in IgAN – a key driver of the pathophysiology? Yusuke Suzuki Audience Q&A All faculty (Moderated by: Co-chairs) Closing remarks Co-chair: Jonathan Barratt MR 110	Emerging Therapies in IgA Nephropathy: The Rationale for Targeting APRIL Organized by Otsuka Visterra Review background on IgAN and the multi-hit IgAN pathogenesis Discuss B-cell biology and rationale for targeting APRIL Present overview of existing clinical evidence supporting targeting APRIL in IgAN MR 111	Looking Beyond Glycemic Control: Cardio Renal and Metabolic Benefits of SGLT2i Organized by Boehringer Ingelheim Looking Beyond Glycemic Control: Cardio Renal and Metabolic Benefits of SGLT2i Professor Dr Carol Pollock Open forum and Q&A Plenary Hall 1
17:00 18:00	Sharing international experience in CKD& SGLT2i: How to identify the right patient at the right moment? Organized by PACE Introduction: New opportunities to tackle the global burden of CKD, the role of SGLT2i Adeera Levin, MD The EMPA-Kidney trial: Broadening the evidence of SGLT2i in CKD Will Herrington, MD SGLT2i in the spectrum of CKD: A call for action Meg Jardine, MD, PhD Panel discussion: Key questions for international practice Natalie Staplin Magdalena Madero David Cherney Roberto Pecoits-Filho MR 110